Action - PPHMD

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

3,15

Prix Achat

0,00

Prix Vente

0,00

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

3,15

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Announcing VanEck Vectors ETFs’ March 2019 Distributions

VanEck announced today its distributions per share for its VanEck Vectors® exchange-traded funds. The following dates apply to...

Announcing VanEck Vectors Equity ETFs December 2018 Distribution

VanEck announced today its regular distribution per share for the following VanEck Vectors® equity exchange-traded fund. ...

VanEck Launches ESPO, ETF Focused on Fast Growing Video Game and eSports Industry

ESPO provides targeted exposure to “the future of sports”: video game and related software developers, streaming services, companies involved...

Announcing VanEck Vectors Equity ETFs’ September 2018 Distributions

VanEck announced today its regular distributions per share for the VanEck Vectors® equity exchange-traded funds. ...

Announcing VanEck Vectors Equity ETFs June 2018 Distributions

VanEck announced today its regular distributions per share for its VanEck Vectors® equity exchange-traded funds. Ex-Date ...

Announcing VanEck Vectors Equity ETFs March 2018 Distributions

VanEck announced today its regular distributions per share for its VanEck Vectors® equity exchange-traded funds. Ex-Date ...

New Study in Clinical Cancer Research Shows Therapeutic Promise of Peregrine's Bavituximab With Radiation in a Lethal Brain Canc

- Treatment in Combination with Radiation Doubled Survival Time and Produced Long-Term Cures in Lethal Brain Cancer Model - - Confirms...

Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies

--Broad New Patent Covers Peregrine's Lead PS-Targeting Antibody Bavituximab and Similar Agents for the Treatment of All Viral Infections-- --New...

Peregrine Pharmaceuticals Regains Full Compliance With Nasdaq Continued Listing Requirements

TUSTIN, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHMD) today announced that on November 3, 2009, the...

Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer

- 28 of 46 (61%) Patients Receiving Bavituximab in Combination with Docetaxel Achieved Objective Tumor Response by End of Planned Treatment Cycles...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

PPHMD - Frequently Asked Questions (FAQ)

What is the current share price?

The current share price of is US$ 3,15

What is the 1 year trading range for share price?

has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
MASS908 Devices Inc	US$ 3,39 (71,21%)	89,75M
FRGTFreight Technologies Inc	US$ 1,555 (50,97%)	62,39M
PTIXProtagenic Therapeutics Inc	US$ 0,3908 (41,44%)	60,01M
JFINJiayin Group Inc	US$ 9,45 (33,66%)	626,72k
MULNMullen Automotive Inc	US$ 2,639 (28,11%)	2,41M
TNYATenaya Therapeutics Inc	US$ 0,4601 (-51,41%)	8,86M
AGHAureus Greenway Holdings Inc	US$ 1,1041 (-49,12%)	1,17M
STISolidion Technology Inc	US$ 0,1665 (-44,74%)	6,26M
JRVRJames River Group Holdings Ltd	US$ 3,25 (-33,67%)	1,42M
STBXStarBox Group Holdings Ltd	US$ 0,5999 (-32,60%)	417,25k
NVDANVIDIA Corporation	US$ 114,7925 (0,64%)	195,76M
UOKAMDJM Ltd	US$ 0,1794 (19,60%)	114,56M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 11,19 (-11,68%)	111,98M
BTOGBit Origin Ltd	US$ 0,381 (19,32%)	109,34M
MASS908 Devices Inc	US$ 3,3801 (70,71%)	88,67M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Peregrine Pharmaceuticals Inc. (MM) (PPHMD)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

PPHMD Dernières nouvelles

Announcing VanEck Vectors ETFs’ March 2019 Distributions

Announcing VanEck Vectors Equity ETFs December 2018 Distribution

VanEck Launches ESPO, ETF Focused on Fast Growing Video Game and eSports Industry

Announcing VanEck Vectors Equity ETFs’ September 2018 Distributions

Announcing VanEck Vectors Equity ETFs June 2018 Distributions

Announcing VanEck Vectors Equity ETFs March 2018 Distributions

New Study in Clinical Cancer Research Shows Therapeutic Promise of Peregrine's Bavituximab With Radiation in a Lethal Brain Canc

Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies

Peregrine Pharmaceuticals Regains Full Compliance With Nasdaq Continued Listing Requirements

Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer

PPHMD - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Peregrine Pharmaceuticals Inc. (MM) (PPHMD) Cours

Peregrine Pharmaceuticals Inc. (MM) (PPHMD)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

PPHMD Dernières nouvelles

Announcing VanEck Vectors ETFs’ March 2019 Distributions

Announcing VanEck Vectors Equity ETFs December 2018 Distribution

VanEck Launches ESPO, ETF Focused on Fast Growing Video Game and eSports Industry

Announcing VanEck Vectors Equity ETFs’ September 2018 Distributions

Announcing VanEck Vectors Equity ETFs June 2018 Distributions

Announcing VanEck Vectors Equity ETFs March 2018 Distributions

New Study in Clinical Cancer Research Shows Therapeutic Promise of Peregrine's Bavituximab With Radiation in a Lethal Brain Canc

Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies

Peregrine Pharmaceuticals Regains Full Compliance With Nasdaq Continued Listing Requirements

Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer

PPHMD - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS